Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0014-4800(78)90081-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alcohol use and HIV suppression after completion of financial incentives for alcohol abstinence and isoniazid adherence: a randomized controlled trial.
EClinicalMedicine
February 2025
Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Background: In a recent randomized trial, six months of financial incentives contingent for recent alcohol abstinence led to lower levels of hazardous drinking, while incentives for recent isoniazid (INH) ingestion had no impact on INH adherence, during TB preventive therapy among persons with HIV (PWH). Whether the short-term incentives influence long-term alcohol use and HIV viral suppression post-intervention is unknown.
Methods: We analyzed twelve-month HIV viral suppression and alcohol use in the Drinkers' Intervention to Prevent Tuberculosis study, a randomized controlled trial among PWH with latent TB and unhealthy alcohol use in south-western Uganda.
Investigating BoLA Class II DRB3*009:02 carrying cattle in Japan.
Vet Anim Sci
March 2025
Veterinary Virology, School of Veterinary Medicine, Rakuno Gakuen University, 582 Midorimachi Bunkyodai, Ebetsu, Hokkaido, 0698501, Japan.
Enzootic bovine leukosis (EBL) is a malignant lymphoma of cattle that is mainly caused by bovine leukemia virus (BLV) infection. In this study, PCR-RFLP was used to investigate the frequency of the DRB3*009:02 allele in several farms with different herd management practices in Japan. A total of 742 Holsteins (384) and Japanese Blacks (230) were used as the sample size for the study, which was larger than the number of cattle in the study area with a confidence level of 95 % and a margin of error of 8.
View Article and Find Full Text PDFLoss of increases type I interferon signalling and reduces pancreatic tumour growth by enhancing immune cell infiltration.
Front Immunol
January 2025
Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer, and despite low incidence rates, it remains the sixth leading cause of cancer related deaths worldwide. Immunotherapy, which aims to enhance the immune system's ability to recognize and eliminate cancer cells, has emerged as a promising approach in the battle against PDAC. PARP7, a mono-ADP-ribosyltransferase, is a negative regulator of the type I interferon (IFN-I) pathway and has been reported to reduce anti-tumour immunity.
View Article and Find Full Text PDFDevelopment and validation of a glycolysis-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer.
Front Immunol
January 2025
Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Background: Bladder cancer (BCa) is one of the most common malignancies worldwide, and its prognostication and treatment remains challenging. The fast growth of various cancer cells requires reprogramming of its energy metabolism using aerobic glycolysis as a major energy source. However, the prognostic and therapeutic value of glycolysis-related genes in BCa remains to be determined.
View Article and Find Full Text PDFA Preliminary Screening Tool for High-Risk Frailty in Older Adults Patients with Pulmonary Tuberculosis.
Clin Interv Aging
January 2025
Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, People's Republic of China.
Objective: To understand the current status and analyse the factors influencing frailty in older adults patients with pulmonary tuberculosis.
Methods: This retrospective case-control study included 204 older adults patients with pulmonary tuberculosis. The enrolled patients were divided into a frailty group (n = 101) and a non-frailty group (n = 103).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!